Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy

I Ray-Coquard, C Borg, Th Bachelot, C Sebban, I Philip, G Clapisson, A Le Cesne, P Biron, F Chauvin, J Y Blay, ELYPSE study group, I Ray-Coquard, C Borg, Th Bachelot, C Sebban, I Philip, G Clapisson, A Le Cesne, P Biron, F Chauvin, J Y Blay, ELYPSE study group

Abstract

A risk model for febrile neutropenia (FN) after conventional cytotoxic chemotherapy, based on early (day 5) lymphopenia and the dose of chemotherapy, has been described. A risk index based on parameters available at day 1 would be easier in daily practice. The objectives of this work were (1) to investigate a risk model for FN using only day 1 blood cell count and (2) to compare the day 1 and day 5 risk models. Three series of patients were used for the delineation and/or validation of these two risk models: (1) the exhaustive cohort of 950 patients treated in the Department of Medicine of the CLB in 1996 (CLB-1996 series), (2) the Elypse 1 series, a prospective series of 321 patients treated in community hospitals and regional cancer centres, and (3) a previously reported Elypse 0 series of 329 patients. Day 1 blood cell count was available in all three series, while day 5 blood cell count was available only in the Elypse 0 and 1 series. In the CLB-1996 series, 92 (9.7%) patients experienced FN; only chemotherapy dose and day 1 lymphopenia < or =700 microl(-1) had an independent prognostic value for FN in multivariate analysis. In patients with both risk factors ('high-risk group'), the incidence of FN was 44, 50 and 61% in the CLB-1996. Elypse 1 and 0 series, respectively, indicating that the 'day 1' risk model enables one to identify patients at high-risk for FN. Besides, the observed incidence of FN in the high-risk group of the 'day 5' model (i.e. patients with day 5 lymphopenia < or =700 microl(-1) and receiving high-risk CT) was 45 and 69% in the Elypse 0 and 1 series, respectively. In the Elypse 1 and 0 series, 15 and 12% of all patients who experienced FN were in the high-risk group of the 'day 1' risk model as compared to 25 and 62% for the high-risk group of the 'day 5' risk model. Both day 1 and day 5 lymphopenia are associated with an increased risk of FN in patients treated with chemotherapy. The 'day 1' model identifies a small population of patients at high risk for FN, but has a lower sensitivity than the day 5 model.

References

    1. Bennett CL, Weeks JA, Somerfield MR, Feinglass J, Smith TJ (1999) Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO clinical practice guidelines Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol 17: 3676–3681
    1. Blay JY, Borg C, Clapisson G, Philip I, Sebban C, Bachelot T, Caux C, Puisieux I, Biron P, Ray-Coquard I (2001) CD4+ and CD56+ lymphopenia (Lyp) as independent risk factors for febrile neutropenia (FN) in a HIV negative cancer patients treated with conventional chemotherapy (CT). Proc Am Soc Clin Oncol 20: 434a (abstract)
    1. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset C, Freyer G, Philip T, Biron P (1996) Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 14: 636–643
    1. Blay JY, Fervers B, Latour JF, Philip T (1995) Standards, Options et Recommandations pour l'utilisation des facteurs de croissance hématopoïétiques en cancérologie. Bull Cancer 82(Suppl 4): 487s–508s
    1. Blay JY, Le Cesne A, Mermet C, Maugard C, Ravaud A, Chevreau C, Sebban C, Guastalla J-P, Biron P, Ray-Coquard I, for the ELYPSE1 Study Group (1998) A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood 92: 405–410
    1. Bodey G (1986) Infection in cancer patients: a continuing association. Am J Med 8(Suppl 1A): 11–26
    1. Bodey GP, Buckley M, Sathe YS et al (1996) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Int Med 64: 328–340
    1. Boogaerts M, Cavalli F, Cortes-Funes H, Gatell JM, Gianni AM, Khayat D, Levy Y, Link H (1995) Granulocyte growth factors: achieving a consensus. Ann Oncol 6: 237–244
    1. Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N (1989) LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7: 1018–1026
    1. Elias A, Ryan L, Sulkes A et al (1989) Response to mesna, doxorubicin, ifosfamide and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 7: 1208–1216
    1. Klastersky J (1993) Febrile neutropenia. Curr Opin Oncol 5: 625–632
    1. Miser JS, Kinsella TJ, Triche TJ et al (1987) Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 5: 1191–1198
    1. Nichols C, Williams S, Loehrer PJ et al (1991) Randomised study of cisplatin dose intensity in poor risk germ cell tumors: a South Eastern Cancer study Group and South West Oncology Group Protocol. J Clin Oncol 9: 1163–1172
    1. Pizzo PA, Hathorn JW, Hiemenz et al (1987) A randomised trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315: 552–558
    1. Ray-Coquard I, Ghesquiere H, Bachelot T, Borg C, Biron P, Sebban C, Le Cesne A, Chauvin F, Blay J-Y (2001) Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer 85: 816–822
    1. Ray-Coquard I, Le Cesne A, Rubio MT, Mermet J, Maugard C, Ravaud A, Chevreau C, Sebban C, Bachelot T, Biron P, Blay JY for the ELYPSE1 Study Group (1999) A risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. J Clin Oncol 17: 2840–2846
    1. Segal BH, Walsh TJ, Holland SM (2001) Infection in the cancer patient. In Cancer. Principles and Practice of Oncology, 6th edn. DeVita VT, Hellman S, Rosenberg SA (eds). pp 2815–2868. Philadelphia, PA: Lippincott
    1. Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective two-center validation of a prediction rule. J Clin Oncol 10: 316–322
    1. Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, Laroque G et al (1988) A randomised trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6: 1377–1387
    1. The American Society of Clinical Oncology (1994) American Society of Clinical Oncology recommendations for the use of hematopoietic colony stimulating factors: evidence based, clinical practice guidelines. J Clin Oncol 12: 2471–2508
    1. The International Antimicrobial Therapy Group of the European Organization for Research and Treatment of Cancer (1978) Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 137: 14–29
    1. Velasquez W, Cabanillas F, Salvador P et al (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high dose Ara-C and dexamethasone (DHAP). Blood 72: 117–122

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera